The role of epigenetics in the biology of multiple myeloma

Blood Cancer Journal

Volumn 4, Issue 5, 2014, Pages

  Dimopoulos, K ^a   Gimsing, P ^a   Gronbaek K ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN DEPENDENT KINASE; CYCLINE; DEATH ASSOCIATED PROTEIN KINASE; HISTONE DEACETYLASE INHIBITOR; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNTRANSLATED RNA; UVOMORULIN; WNT PROTEIN;

APOPTOSIS; CELL CYCLE REGULATION; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; HISTONE MODIFICATION; HUMAN; MULTIPLE MYELOMA; PATHOGENESIS; REVIEW; TUMOR SUPPRESSOR GENE; ANIMAL; GENETIC EPIGENESIS; GENETICS;

ANIMALS; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; HUMANS; MULTIPLE MYELOMA;

EID: 84901987401     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.29     Document Type: Review

References (101)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
2. Landgren O, Kyle Ra, Pfeiffer RM, Katzmann Ja, Caporaso NE, Hayes RB et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412-5417.
3. Sharma A, Heuck CJ, Fazzari MJ, Mehta J, Singhal S, Greally JM et al. DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. Wiley Interdiscip Rev Syst Biol Med 2010; 2: 654-669.
4. Chapman Ma, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467-472.
5. Dimopoulos K, Gimsing P, Grønbaek K. Aberrant microRNA expression in multiple myeloma. Eur J Haematol 2013; 91: 95-105.
6. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart aK et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23: 2210-2221.
7. Jones Pa. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012; 13: 484-492.
8. Walton EL, Francastel C, Velasco G. Maintenance of DNA methylation: Dnmt3b joins the dance. Epigenetics 2011; 6: 1373-1377.
9. Williams K, Christensen J, Helin K. DNA methylation: TET proteins-guardians of CpG islands? EMBO Rep 2012; 13: 28-35.
10. Grønbaek K, Hother C, Jones PA. Epigenetic changes in cancer. APMIS 2007; 115: 1039-1059.
11. Walker Ba, Wardell CP, Chiecchio L, Smith EM, Boyd KD, Neri A et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 2011; 117: 553-562.
12. Heuck CJ, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S et al. Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. J Immunol 2013; 190: 2966-2975.
13. Kaiser MF, Johnson DC, Wu P, Walker Ba, Brioli A, Mirabella F et al. Global methylation analysis identifies prognostically important epigenetically inactivated tumour suppressor genes in multiple myeloma. Blood 2013; 122: 219-226.
14. Bollati V, Fabris S, Pegoraro V, Ronchetti D, Mosca L, Deliliers GL et al. Differential repetitive DNA methylation in multiple myeloma molecular subgroups. Carcinogenesis 2009; 30: 1330-1335.
15. Amodio N, Leotta M, Bellizzi D, Di Martino MT, D'Aquila P, Lionetti M et al. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget 2012; 3: 1246-1258.
16. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S-H et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell 2011; 19: 17-30.
17. Song SJ, Ito K, Ala U, Kats L, Webster K, Sun SM et al. The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell 2013; 13: 87-101.
18. Li Z, Cai X, Cai C-L, Wang J, Zhang W, Petersen BE et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011; 118: 4509-4518.
19. Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams DR et al. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci USA 2010; 107: 7904-7909.
20. Struhl K, Segal E. Determinants of nucleosome positioning. Nat Struct Mol Biol 2013; 20: 267-273.
21. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705.
22. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997; 389: 349-352.
23. Barski A, Cuddapah S, Cui K, Roh T-Y, Schones DE, Wang Z et al. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129: 823-837.
24. Schwartz YB, Pirrotta V. Polycomb complexes and epigenetic states. Curr Opin Cell Biol 2008; 20: 266-273.
25. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008; 40: 741-750.
26. Ernst J, Kellis M. Discovery and characterization of chromatin states for systematic annotation of the human genome. Nat Biotechnol 2010; 28: 817-825.
27. Ucar D, Hu Q, Tan K. Combinatorial chromatin modification patterns in the human genome revealed by subspace clustering. Nucleic Acids Res 2011; 39: 4063-4075.
28. Linghu C, Zheng H, Zhang L, Zhang J. Discovering common combinatorial histone modification patterns in the human genome. Gene 2013; 518: 171-178.
29. Cai Y, Geutjes E-J, de Lint K, Roepman P, Bruurs L, Yu L-R et al. The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes. Oncogene 2014; 33: 2157-2168.
30. Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet 2013; 14: 765-780.
31. Croonquist Pa, Van Ness B. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 2005; 24: 6269-6280.
32. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler Ha, Barth TFE et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008; 112: 4202-4212.
33. Pichiorri F, Suh S-S, Ladetto M, Kuehl M, Palumbo T, Drandi D et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008; 105: 12885-12890.
34. Stec I, Wright TJ, van Ommen GJ, de Boer Pa, van Haeringen a, Moorman a F et al. WHSC1, a 90kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma. Hum Mol Genet 1998; 7: 1071-1082.
35. Marango J, Shimoyama M, Nishio H, Meyer Ja, Min D-J, Sirulnik A et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 2008; 111: 3145-3154.
36. Pei H, Zhang L, Luo K, Qin Y, Chesi M, Fei F et al. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 2011; 470: 124-128.
37. Martinez-Garcia E, Popovic R, Min D-J, Sweet SMM, Thomas PM, Zamdborg L et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 2011; 117: 211-220.
38. Kuo AJ, Cheung P, Chen K, Zee BM, Kioi M, Lauring J et al. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell 2011; 44: 609-620.
39. Huang Z, Wu H, Chuai S, Xu F, Yan F, Englund N et al. NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma. Cancer Res 2013; 73: 6277-6288.
40. Schmitges FW, Prusty AB, Faty M, Stü tzer A, Lingaraju GM, Aiwazian J et al. Histone methylation by PRC2 is inhibited by active chromatin marks. Mol Cell 2011; 42: 330-341.
41. Yang P, Guo L, Duan ZJ, Tepper CG, Xue L, Chen X et al. Histone methyl-transferase NSD2/MMSET mediates constitutive NF-kB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol 2012; 32: 3121-3131.
42. Djebali S, Davis Ca, Merkel A, Dobin A, Lassmann T, Mortazavi A et al. Landscape of transcription in human cells. Nature 2012; 489: 101-108.
43. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
44. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007; 104: 15805-15810.
45. Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, Hirata H et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 2009; 28: 1714-1724.
46. Wong K-Y, Liang R, So C-C, Jin D-Y, Costello JF, Chim C-S. Epigenetic silencing of MIR203 in multiple myeloma. Br J Haematol 2011; 154: 569-578.
47. Wong KY, Yim RLH, So CC, Jin D-Y, Liang R, Chim CS. Epigenetic inactivation of the MIR34B/C in multiple myeloma. Blood 2011; 118: 5901-5904.
48. Pichiorri F, Suh S-S, Rocci A, De Luca L, Taccioli C, Santhanam R et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010; 18: 367-381.
49. Chi J, Ballabio E, Chen X-H, Kusec R, Taylor S, Hay D et al. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct 2011; 6: 23.
50. Corthals SL, Sun SM, Kuiper R, de Knegt Y, Broyl a, van der Holt B et al. MicroRNA signatures characterize multiple myeloma patients. Leukemia 2011; 25: 1784-1789.
51. Munker R, Liu C-G, Taccioli C, Alder H, Heerema N. MicroRNA profiles of drug-resistant myeloma cell lines. Acta Haematol 2010; 123: 201-204.
52. Ronchetti D, Todoerti K, Tuana G, Agnelli L, Mosca L, Lionetti M et al. The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma. Blood Cancer J 2012; 2: e96.
53. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998; 17: 5001-5014.
54. Deshpande A, Sicinski P, Hinds PW. Cyclins and cdks in development and cancer: a perspective. Oncogene 2005; 24: 2909-2915.
55. Witkiewicz AK, Knudsen KE, Dicker AP, Knudsen ES. The meaning of p16ink4a expression in tumors: Functional significance, clinical associations and future developments. Cell Cycle 2011; 10: 2497-2503.
56. Bergsagel PL, Kuehl WM. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev 2003; 194: 96-104.
57. Amodio N, Di Martino MT, Foresta U, Leone E, Lionetti M, Leotta M et al. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis 2012; 3: e436.
58. O'Donnell Ka, Wentzel Ea, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435: 839-843.
59. Chim CS, Fung TK, Liang R. Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS. Leukemia 2003; 17: 2533-2535.
60. Mateos MV, García-Sanz R, López-Pérez R, Moro MJ, Ocio E, Hernández J et al. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol 2002; 118: 1034-1040.
61. Hatzimichael E, Benetatos L, Dasoula A, Dranitsaris G, Tsiara S, Georgiou I et al. Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia. Leuk Res 2009; 33: 1272-1275.
62. Stanganelli C, Arbelbide J, Fantl DB, Corrado C, Slavutsky I. DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance. Ann Hematol 2010; 89: 191-199.
63. Seidl S, Ackermann J, Kaufmann H, Keck A, Nösslinger T, Zielinski CC et al. DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer 2004; 100: 2598-2606.
64. Gonzalez-Paz N, Chng WJ, McClure RF, Blood E, Oken MM, Van Ness B et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 2007; 109: 1228-1232.
65. Niehrs C. The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol 2012; 13: 767-779.
66. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008; 8: 387-398.
67. Martello G, Zacchigna L, Inui M, Montagner M, Adorno M, Mamidi A et al. MicroRNA control of Nodal signalling. Nature 2007; 449: 183-188.
68. Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009; 113: 6669-6680.
69. Sun C-Y, She X-M, Qin Y, Chu Z-B, Chen L, Ai L-S et al. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis 2012; 00: 1-10.
70. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003; 116(Pt 13): 2627-2634.
71. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483-2494.
72. Cha YH, Kim NH, Park C, Lee I, Kim HS, Yook JI. MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. Cell Cycle 2012; 11: 1273-1281.
73. Huang K, Zhang J-X, Han L, You Y-P, Jiang T, Pu P-Y et al. MicroRNA roles in beta-catenin pathway. Mol Cancer 2010; 9: 252.
74. Onder TT, Gupta PB, Mani Sa, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008; 68: 3645-3654.
75. Kam Y, Quaranta V. Cadherin-bound beta-catenin feeds into the Wnt pathway upon adherens junctions dissociation: evidence for an intersection between beta-catenin pools. PLoS One 2009; 4: e4580.
76. Chim C-S, Liang R, Leung M-H, Yip S-F, Kwong Y-L. Aberrant gene promoter methylation marking disease progression in multiple myeloma. Leukemia 2006; 20: 1190-1192.
77. Cao M, Seike M, Soeno C, Mizutani H, Kitamura K, Minegishi Y et al. MiR-23a regulates TGF-b-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. Int J Oncol 2012; 41: 869-875.
78. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374(Pt 1): 1-20.
79. Collins AS, McCoy CE, Lloyd AT, O'Farrelly C, Stevenson NJ. miR-19a: an effective regulator of SOCS3 and enhancer of JAK-STAT signalling. PLoS One 2013; 8: e69090.
80. Xiong Q, Zhong Q, Zhang J, Yang M, Li C, Zheng P et al. Identification of novel miR-21 target proteins in multiple myeloma cells by quantitative proteomics. J Proteome Res 2012; 11: 2078-2090.
81. Löffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermü ller J, Kretzschmar AK et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007; 110: 1330-1333.
82. Wang X, Li C, Ju S, Wang Y, Wang H, Zhong R. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation. Leuk Lymphoma 2011; 52: 1991-1998.
83. Xiong H, Du W, Zhang Y-J, Hong J, Su W-Y, Tang J-T et al. Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells. Mol Carcinog 2012; 51: 174-184.
84. Martoriati A, Doumont G, Alcalay M, Bellefroid E, Pelicci PG, Marine J-C. dapk1, encoding an activator of a p19ARF-p53-mediated apoptotic checkpoint, is a transcription target of p53. Oncogene 2005; 24: 1461-1466.
85. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
86. Khong T, Sharkey J, Spencer A. The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Haematologica 2008; 93: 860-869.
87. Spange S, Wagner T, Heinzel T, Krämer OH. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 2009; 41: 185-198.
88. Todoerti K, Barbui V, Pedrini O, Lionetti M, Fossati G, Mascagni P et al. Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. Haematologica 2010; 95: 260-269.
89. Lamottke B, Kaiser M, Mieth M, Heider U, Gao Z, Nikolova Z et al. The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases. Eur J Haematol 2012; 88: 406-415.
90. Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 2013; 122: 2331-2337.
91. Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol 2013; 14: 1129-1140.
92. Offidani M, Polloni C, Cavallo F, Liberati AM, Ballanti S, Pulini S et al. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma 2012; 53: 1722-1727.
93. New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol 2012; 6: 637-656.
94. Santo L, Hideshima T, Kung AL, Tseng J, Tamang D, Yang M et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012; 119: 2579-2589.
95. Spannhoff A, Hauser A-T, Heinke R, Sippl W, Jung M. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. ChemMed-Chem 2009; 4: 1568-1582.
96. Lovén J, Hoke Ha, Lin CY, Lau A, Orlando Da, Vakoc CR et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013; 153: 320-334.
97. Chng W-J, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011; 25: 1026-1035.
98. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4: 143-159.
99. Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012; 18: 6260-6270.
100. Fu S, Kurzrock R. Development of curcumin as an epigenetic agent. Cancer 2010; 116: 4670-4676.
101. Sung B, Kunnumakkara AB, Sethi G, Anand P, Guha S, Aggarwal BB. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 2009; 8: 959-970.